ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ASCO

ASTRAZENECA UPDATES ON THE RAPID PROGRESS OF ITS ONCOLOGY PIPELINE AT ASCO 2014

The following amendment has been made to the 'ASTRAZENECA UPDATES ON ONCOLOGY
PIPELINE AT ASCO' announcement released today.

Please note the correct date of the analyst and investor presentation is 2 June
2014. All other details remain unchanged.

AstraZeneca provided an update on the rapid development of its oncology pipeline
at a briefing for analysts and investors on 2 June 2014, as compelling data from
over 40 scientific abstracts related to AstraZeneca and MedImmune
investigational medicines were presented at the American Society of Clinical
Oncology (ASCO) meeting in Chicago.

Pascal Soriot, Chief Executive Officer of AstraZeneca said: "ASCO 2014 is a
pivotal meeting for AstraZeneca - we have a lot to be proud of. Our growing
oncology pipeline is underpinned by exciting science and great talent. We have
compelling new data on important mid to late stage assets, which clearly
demonstrate our potential to transform the way cancer is treated and the right
people to move them forward. We remain resolute in our ambition to bring these
next-generation cancer medicines to patients as fast as possible."

Highlights of the analyst and investor presentation were:

Small molecules
Data from the large Phase I study of AZD9291 (presented on Saturday 31 May)
showed strong activity as a once-daily monotherapy, with clinical responses
observed in an EGFRm+ population of patients with non-small cell lung cancer
(NSCLC) who previously failed on EGFR TKIs and also in patients with the T790M
resistance mutation. 94% of T790M positive (T790M+) patients saw their tumours
shrink or become stable. In addition, 64% of T790M+ patients achieved tumour
shrinkage of 30% or more. The most common adverse events were low grade
diarrhoea rash and nausea.

The company anticipates filing for regulatory approval in the United States for
AZD9291 in the second half of 2015 or potentially as early as the first quarter.

Data from a Phase II study by the US National Cancer Institute (NCI) were
presented as a late-breaking abstract (Saturday 31 May), investigating the
combination of olaparib and cediranib in patients with platinum-sensitive high
-grade serous ovarian cancer. The data showed that the combination of the two
orally-administered investigational medicines nearly doubled the time it took
for patients' tumours to progress (progression-free survival) and improved
objective response rate (ORR), compared to treatment with olaparib alone.

AstraZeneca supports the NCI's plans to move the combination forward into Phase
III development.

Briggs Morrison, Executive Vice President and Chief Medical Officer said: "This
is extremely exciting data and among the longest progression-free survival seen
by treatments for patients with platinum-sensitive high-grade serous ovarian
cancer. What is even more compelling is that the combination of olaparib and
cediranib has the potential to replace chemotherapy. We look forward to seeing
the combination move into Phase III to further explore the potential benefits
for patients who currently have very limited treatment options."

Immuno-oncology
Multiple Phase I data sets for MEDI4736 - MedImmune's investigational,
engineered, human monoclonal antibody directed against programmed cell death
ligand 1 (PD-L1) -showed durable clinical activity and tolerability across a
range of tumour types.

In the Phase I dose escalation study, reduction of tumour burden was seen at
multiple dose levels as early as six weeks, and clinical activity was maintained
over one year. There was a very low frequency of drug-related serious adverse
events, and no dose-limiting toxicities were observed.

Data from the dose expansion phase provided further information on the clinical
activity and tolerability profile of MEDI4736, showing early evidence of
clinical activity in over 300 patients in multiple tumour types.

The Phase I study results, coupled with the pre-clinical data and validation of
this target, supported the recent acceleration of MEDI4736 into Phase III
clinical trials.

At the analyst and investor briefing AstraZeneca also confirmed the enlarged
recruitment target for the tremelimumab Phase II study in mesothelioma, making
it a registration trial.

In addition to data presented at ASCO, AstraZeneca also provided an update on
the Phase I dose escalation study of MEDI4736 in combination with tremelimumab
for patients with refractory NSCLC. Early data has shown encouraging efficacy
for the combination in NSCLC and no dose limiting toxicities across the five
dose levels assessed to date.

AstraZeneca plans to initiate a Phase III study investigating MEDI4736 in
combination with tremelimumab for patients with NSCLC, as an additional arm of
the ARCTIC clinical programme.

Bahija Jallal, Executive Vice President, MedImmune said:"Immuno-oncology is
transforming the landscape of cancer treatment. It is developing at a rapid pace
and we're excited to play a key role in this critical area with our promising
science. With the AstraZeneca and MedImmune combined portfolios, we are uniquely
positioned to explore this promising therapeutic approach and have already
initiated multiple combination studies with MEDI4736."

Audio replay and the presentation from the analyst and investor event will be
available on the investor pages of the AstraZeneca website
here (http://www.astrazeneca.com/Investors).

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler                        +44 20 7604 8030 (UK/Global)
Ayesha Bharmal                        +44 20 7604 8034 (UK/Global)
Jacob Lund                                +46 8 553 260 20 (Sweden)
Michele Meixell                          + 1 302 885 6351 (US)

Investor Enquiries
Karl Hård                                   +44 20 7604 8123  mob: +44 7789
654364
Colleen Proctor                         + 1 302 886 1842      mob: +1 302 357
4882
Anthony Brown                          +44 20 7604 8067    mob: +44 7585 404943
Jens Lindberg                            +44 20 7604 8414    mob: +44 7557
319729

3 June 2014

-ENDS-